Improving access to melarsomine therapy: treating canine heartworm infection in a high-volume, outpatient community clinic setting

Table 5 GLMM investigating the effects on VT/VA-observed adverse reactions

Fixed effect	Estimate	SE	z value	P ( >\|z\|)
(Intercept)	1.472	0.186	7.925	< 0.001*
Injection appointment 2	−0.463	0.175	−2.64	0.008*
Injection appointment 3	−0.755	0.183	−4.121	< 0.001*
Relative timing of melarsomine injection	0.005	0.002	2.245	0.0248*
Timing of sedative administration	−0.347	0.208	−1.665	0.096
Secondary sedation administration	0.123	0.229	0.0.538	0.590
Patient movement during administration	0.144	0.169	0.854	0.393
Relative timing of melarsomine injection * Timing of sedative administration	−0.008	0.003	−2.451	0.0142*

ISSN: 1756-3305